Literature DB >> 6209028

The tumorigenicity of 5-azacytidine in the male Fischer rat.

B I Carr, J G Reilly, S S Smith, C Winberg, A Riggs.   

Abstract

5-Azacytidine was administered to young adult male Fischer rats. Tumors were found in 31 out of 70 rats that had received 5-azacytidine and survived 18 months from the start of the experiment. Several rats had multiple primary tumors. In the rats that were tested for complete carcinogenicity a variety of tumor types was found. These included acute leukemia and malignant reticuloendotheliosis, and tumors of the testis, skin, and bronchus. No hepatic tumors were found in the group that was tested for hepatic tumor initiation. Hepatocellular carcinomas were found only in the group that was examined for hepatic tumor promotion by receiving a prior initiating dose of diethylnitrosamine. No tumors were found in the age controls. Thus, in these initial experiments, 5-azacytidine appeared to be a complete carcinogen, inducing tumors in several organs, and a tumor promoter but not a complete carcinogen for the liver.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209028     DOI: 10.1093/carcin/5.12.1583

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment.

Authors:  S W Lee; C Tomasetto; K Swisshelm; K Keyomarsi; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 2.  Epigenetic programming of mesenchymal stem cells from human adipose tissue.

Authors:  Andrew C Boquest; Agate Noer; Philippe Collas
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 4.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

Review 5.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

6.  Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro.

Authors:  D Roa; P Kopsombut; M P Aguinaga; E A Turner
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

7.  Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.

Authors:  Susan P Perrine; Serguei A Castaneda; Michael S Boosalis; Gary L White; Brandon M Jones; Regine Bohacek
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

Review 8.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 9.  Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.

Authors:  Jong Hun Lee; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Ah-Ng Tony Kong
Journal:  Pharmacol Ther       Date:  2012-10-03       Impact factor: 12.310

10.  5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate.

Authors:  V K Pathak; H M Temin
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.